Erratum to Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis [Muscle Nerve. 51, 1, 2015, 14-18] DOI: 10.1002/mus.24470;Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis

Muscle and Nerve

Volumn 51, Issue 1, 2015, Pages 14-18

  Turner, Martin R ^a   Benatar, Michael ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Motor neuron disease; Neurochemistry; Neuroimaging; Trial

Indexed keywords

BIOLOGICAL MARKER;

AMYOTROPHIC LATERAL SCLEROSIS; HUMAN; METABOLISM;

AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS; HUMANS;

EID: 84916912474     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24543     Document Type: Erratum

References (40)

1. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, de Carvalho M, et al. Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 2013;12:310-322.
2. Bradley WG. Biological markers in amyotrophic lateral sclerosis: help or hindrance? J Neurol 1999;246(suppl 3):iii13-15.
3. Poser CM, Johnson M, Bunch LD. Serum amino acid studies in amyotrophic lateral sclerosis I. results of arginine tolerance tests. Arch Neurol 1965;12:604-609.
4. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009;8:94-109.
5. Bowser R, Turner MR, Shefner J. Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol 2011;7:631-638.
6. Turner MR, Agosta F, Bede P, Govind V, Lule D, Verstraete E. Neuroimaging in amyotrophic lateral sclerosis. Biomark Med 2012;6:319-337.
7. Vucic S, Ziemann U, Eisen A, Hallett M, Kiernan MC. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry 2013;84:1161-1170.
8. Rutkove SB, Caress JB, Cartwright MS, Burns TM, Warder J, David WS, et al. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler 2012;13:439-445.
9. Makki AA, Benatar M. Diagnostic accuracy of thoracic paraspinal electromyography in amyotrophic lateral sclerosis. J Clin Neurophysiol 2007;24:298-300.
10. Poste G. Bring on the biomarkers. Nature 2011;469:156-157.
11. Mitchell JD, Callagher P, Gardham J, Mitchell C, Dixon M, Addison-Jones R, et al. Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)-a 20-year review: can we do better? Amyotroph Lateral Scler 2010;11:537-541.
12. Swash M. Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2012;83:659-662.
13. Swank RL, Putnam TJ. Amyotrophic lateral sclerosis and related conditions: a clinical analysis. Arch Neurol Psychiatry 1943;49:151-177.
14. Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry 2003;74:995-997.
15. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:15-21.
16. Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. Pract Neurol 2013;13:153-164.
17. Brownell B, Oppenheimer DR, Hughes JT. The central nervous system in motor neurone disease. J Neurol Neurosurg Psychiatry 1970;33:338-357.
18. Ince PG, Evans J, Knopp M, Forster G, Hamdalla HH, Wharton SB, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003;60:1252-1258.
19. Bakola E, Kokotis P, Zambelis T, Karandreas N. Inappropriate surgeries in amyotrophic lateral sclerosis: a still considerable issue. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:315-317.
20. Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology 2013;80:1590-1597.
21. Feynman R. Cargo cult science. Eng Sci 1974;37:10-13.
22. Bruijn L, Cudkowicz M. Opportunities for improving therapy development in ALS. Amyotroph Lateral Scler Frontotemporal Degen 2014;15:169-173.
23. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135:847-852.
24. Chiò A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2013-306589.
25. Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2013-306865.
26. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 2006;66:265-267.
27. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-216.
28. Su XW, Simmons Z, Mitchell RM, Kong L, Stephens HE, Connor JR. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. JAMA Neurol 2013;70:1505-1511.
29. Blain CR, Brunton S, Williams VC, Leemans A, Turner MR, Andersen PM, et al. Differential corticospinal tract degeneration in homozygous 'D90A' SOD-1 ALS and sporadic ALS. J Neurol Neurosurg Psychiatry 2011;82:843-849.
30. Welsh RC, Jelsone-Swain LM, Foerster BR. The utility of independent component analysis and machine learning in the identification of the amyotrophic lateral sclerosis diseased brain. Front Hum Neurosci 2013;7:251.
31. Fekete T, Zach N, Mujica-Parodi LR, Turner MR. Multiple kernel learning captures a systems-level functional connectivity biomarker signature in amyotrophic lateral sclerosis. PloS One 2013;8:e85190.
32. Wuolikainen A, Hedenstrom M, Moritz T, Marklund SL, Antti H, Andersen PM. Optimization of procedures for collecting and storing of CSF for studying the metabolome in ALS. Amyotroph Lateral Scler 2009;10:229-236.
33. Lehnert S, Costa J, de Carvalho M, Kirby J, Kuzma-Kozakiewicz M, Morelli C, et al. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:344-350.
34. Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler 2012;13:1-10.
35. Turner MR, Grosskreutz J, Kassubek J, Abrahams S, Agosta F, Benatar M, et al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2011;10:400-403.
36. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999;282:1061-1066.
37. Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012;79:1732-1739.
38. Douaud G, Filippini N, Knight S, Talbot K, Turner MR. Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain 2011;134:3470-3479.
39. Mitchell RM, Simmons Z, Beard JL, Stephens HE, Connor JR. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 2010;42:95-103.
40. Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, McGrath M, et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degen 2013;14(suppl 1):19-32.